Welcome to our dedicated page for HYTN Innovations news (Ticker: HYTNF), a resource for investors and traders seeking the latest updates and insights on HYTN Innovations stock.
HYTN Innovations Inc. manufactures pharmaceutical-grade products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids, under regulated quality systems. Company updates commonly address Health Canada licensing, Good Manufacturing Practices inspections, Drug Establishment Licence and Cannabis Drug Licence scope, and the fabrication, packaging, labelling and distribution of cannabinoid-based pharmaceutical products.
Recurring developments also cover GMP-manufactured cannabis oils, active pharmaceutical ingredients, live resin vape cartridges, dried flower processing, and HYTN’s Hermetic Autogenous Remediation™ service for microbial-burden reduction. International commercialization updates focus on regulated medical cannabis supply channels and product-release procedures in markets such as Germany, the United Kingdom and Australia, alongside governance changes and capital-structure matters.
HYTN Innovations (OTC: HYTNF) announced an amendment to its Health Canada Drug Establishment Licence following a GMP inspection of its Kelowna facility dated May 7, 2026. The DEL now authorizes fabrication, packaging, and labeling of non-sterile APIs in solid and non-solid forms and adds pharmaceutical oil as a finished dosage form.
The expanded scope supports HYTN’s regulated GMP manufacturing activities for pharmaceutical and cannabinoid supply chains, subject to product-specific, customer-specific, import, release, drug control, and jurisdictional requirements. The release notes potential EU import facilitation for Canadian APIs, but clarifies this is not automatic EU market approval.
HYTN Innovations (OTC: HYTNF) announced the successful GMP manufacture, release and export of 1,000 one-gram live resin vape cartridges for sale in Australia’s regulated medical cannabis market.
Health Canada inspection outcomes expanded HYTN’s Drug Establishment Licence to include oil as an API and as a finished dosage form, enabling regulated international production and export to markets including Germany, the UK and Australia.
HYTN (OTC: HYTNF) announced Board approval of a proposed spin-out to create a dedicated peptide drug development company ("SpinCo") focused on a pre-clinical subcutaneous BPC-157 candidate for refractory ligament disorders. The plan contemplates a concurrent non-brokered private placement of up to CAD $1,000,000, transfer of GMP assets and know-how, selection of a Canadian GMP sterile manufacturer and an approved dose-controlled medical device platform, and regulatory positioning for CTA and SAP pathways. Completion is subject to definitive documentation, securities and exchange reviews, and other customary approvals.
HYTN (OTC: HYTNF) launched Hermetic Autogenous Remediation™ (HARd), a proprietary GMP‑validated remediation service for dried cannabis flower, on April 17, 2026. HARd reportedly achieves multi‑log microbial reductions per internal validation and third‑party testing and was commercially released in Germany.
HYTN says HARd avoids heat, radiation, chemical fumigants, and dehydration, and will be offered to domestic and international counterparties under EU‑GMP‑aligned quality systems; the company cautions this is not regulatory approval of the methodology.
HYTN Innovations (OTC: HYTNF) announced successful release of previously exported wholesale cannabis products for sale in Germany on March 27, 2026. The release followed completion of required import, quality control, and market release procedures for Germany’s regulated medical cannabis market.
The company also accepted a reorder for additional wholesale product, which HYTN says validates its GMP platform and supports its strategy to expand pharmaceutical-grade cannabis sales into highly regulated international markets.
HYTN Innovations (OTC: HYTNF) appointed Fabian Monaco to its Board of Directors effective March 20, 2026. Monaco brings venture, private equity and capital markets experience, including leading Gage Growth to $100M revenue and a sale of over $500M.
The company also engaged MCS Market Communication Service for digital marketing starting March 23, 2026 for approximately 60 days with a budgeted fee of €100,000; no securities will be issued as payment.
HYTN Innovations (OTC: HYTNF) welcomed a U.S. executive order issued on December 18, 2025 directing federal agencies to begin the administrative process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act.
This reclassification, if implemented, would treat cannabis as a federally controlled pharmaceutical with oversight by the FDA and DEA, and require compliance with federal manufacturing, prescribing, importing, and research rules rather than only state frameworks.
HYTN highlights existing capabilities: a Health Canada Drug Establishment Licence, a Certificate of GMP Conformity applicable to the U.S., a Cannabis Drug Licence, and established export operations to the UK, Germany, and Australia, positioning the company to evaluate emerging U.S. opportunities as the process advances.
HYTN Innovations (OTC:HYTNF) has secured a Cannabis Drug Licence (CDL) from Health Canada on July 2, 2025, marking a significant expansion of its pharmaceutical manufacturing capabilities. This licence complements HYTN's existing Drug Establishment Licence (DEL) and cannabis licences, positioning the company to manufacture cannabis-derived pharmaceutical drugs.
As a GMP-certified manufacturer, HYTN can now support clinical research, pursue drug approvals, and develop prescription pharmaceutical products. The company is also progressing with EudraGMDP registration for European markets and can serve as a Contract Development and Manufacturing Organization (CDMO) partner for clinical-stage companies.
The market potential is demonstrated by Epidiolex, a CBD-derived prescription drug that generated $972.4 million in sales in 2024 with an 88.2% gross margin.
HYTN Innovations (OTC: HYTNF) has secured Good Manufacturing Practices (GMP) certificates from Health Canada for its Kelowna manufacturing facility, specifically for the United States, Bermuda, and Israel. The certificates, requested in February, validate HYTN's production processes and are important for drug registrations in these jurisdictions.
The company's Drug Establishment License (DEL) enables the fabrication, packaging, and labeling of non-sterile pharmaceuticals containing cannabis and psilocybin. HYTN currently operates in Canada, UK, Germany, and Australia, with these new certifications positioning them for expansion into additional markets.